Literature DB >> 15940142

Report of the Topical Calcineurin Inhibitor Task Force of the American College of Allergy, Asthma and Immunology and the American Academy of Allergy, Asthma and Immunology.

Luz Fonacier1, Jonathan Spergel, Ernest N Charlesworth, David Weldon, Vincent Beltrani, Jan Bernhisel-Broadbent, Mark Boguniewicz, Donald Y M Leung.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15940142     DOI： 10.1016/j.jaci.2005.04.006

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN： 0091-6749            Impact factor:   10.793


× No keyword cloud information.
  21 in total

Review 1.  Safety of topical calcineurin inhibitors in atopic dermatitis: evaluation of the evidence.

Authors:  Jonathan M Spergel; Donald Y M Leung
Journal:  Curr Allergy Asthma Rep       Date:  2006-07       Impact factor: 4.806

2.  Questions and answers on immunization.

Authors:  Stéphane Paulus; Stuart Turvey
Journal:  Paediatr Child Health       Date:  2006-02       Impact factor: 2.253

3.  Pathways to managing atopic dermatitis: consensus from the experts.

Authors:  Mark G Lebwohl; James Q Del Rosso; William Abramovits; Brian Berman; David E Cohen; Emma Guttman; Anthony J Mancini; Lawrence A Schachner
Journal:  J Clin Aesthet Dermatol       Date:  2013-07

Review 4.  Atopic dermatitis in children: clinical features, pathophysiology, and treatment.

Authors:  Jonathan J Lyons; Joshua D Milner; Kelly D Stone
Journal:  Immunol Allergy Clin North Am       Date:  2014-11-21       Impact factor: 3.479

5.  Association Between Malignancy and Topical Use of Pimecrolimus.

Authors:  David J Margolis; Katrina Abuabara; Ole J Hoffstad; Joy Wan; Denise Raimondo; Warren B Bilker
Journal:  JAMA Dermatol       Date:  2015-06       Impact factor: 10.282

Review 6.  Topical calcineurin inhibitors and lymphoma risk: evidence update with implications for daily practice.

Authors:  Elaine C Siegfried; Jennifer C Jaworski; Adelaide A Hebert
Journal:  Am J Clin Dermatol       Date:  2013-06       Impact factor: 7.403

Review 7.  Topical calcineurin inhibitors in pediatric atopic dermatitis: a critical analysis of current issues.

Authors:  Seth J Orlow
Journal:  Paediatr Drugs       Date:  2007       Impact factor: 3.022

Review 8.  Topical pimecrolimus: a review of its use in the management of pediatric atopic dermatitis.

Authors:  Lily P H Yang; Monique P Curran
Journal:  Paediatr Drugs       Date:  2009       Impact factor: 3.022

Review 9.  The US FDA 'black box' warning for topical calcineurin inhibitors: an ongoing controversy.

Authors:  Johannes Ring; Matthias Möhrenschlager; Verena Henkel
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

Review 10.  A safety assessment of topical calcineurin inhibitors in the treatment of atopic dermatitis.

Authors:  Mark Lebwohl; Tara Gower
Journal:  MedGenMed       Date:  2006-10-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.